Pharmacokinetics, Mechanism, and Docking Study of Antioxidant Aryl-Bisthiourea Derivatives for Alzheimer's Disease

2Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Novel aryl-bisthiourea derivatives (3 a–3 j) were synthesized by a two-step route for the study of free-radical scavenging property and acetylcholinesterase enzyme (AChE) inhibition study. The effect of the electronic environment on the aryl structure of ArBTU on the AChE inhibition was studied. Lineweaver-Burk plot was used for kinetic study of inhibition of AChE by using ArBTU derivatives which exhibited very good bioactivity of inhibition against acetylcholinesterase enzyme. Central Nervous System (CNS) permeability and the Blood-Brain Barrier values of all ArBTU derivatives (3 a–3 j) were also similar to the reference value (>−2 logPS< −3 and >−0.3 log BB< −1), respectively. The molecular docking study of derivative 3 g presented a very good interactions with tested protein. The mechanism of AChE inhibition was found from the kinetic studies of novel ArBTU derivatives. A pharmacokinetic study of AChE inhibition was also evaluated. ArBTU derivatives (3 a–3 j) exhibited the best lead-like potential. Molecular docking study described the binding ability of the highly effective derivative 3 g with the acetylcholinesterase enzyme.

Cite

CITATION STYLE

APA

Bahadur, A., Iqbal, S., Shoaib, M., Zulqarnain, M., Shah, M., Abd-Rabboh, H. S. M., … Zaman, A. (2021). Pharmacokinetics, Mechanism, and Docking Study of Antioxidant Aryl-Bisthiourea Derivatives for Alzheimer’s Disease. ChemistrySelect, 6(33), 8560–8565. https://doi.org/10.1002/slct.202101634

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free